Advertisement

Relating Membrane Receptors to Drugs

  • Arnold M. Katz
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 121)

Abstract

Comparison of the interactions of propranolol, nimodipine, and amiodarone with membrane lipids, and the duration of their pharmacological effects suggests that the pharmacokinetics of a drug may be partly determined by its location within the phospholipid bilayer.

Keywords

Calcium Channel Antagonist Membrane Bilayer High Partition Coefficient Cardiac Drug Dihydropyridine Calcium Channel Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Straub W: Die Bedeutung der Zellmembran fuer die Wirkung chemischer Stoffe auf den Organismus. Verh Ges Deutsch Naturf Arzte. 1912; 1–25.Google Scholar
  2. 2.
    Seeman P: The membrane actions of anesthetics and tranquilizers. Pharm Rev 1972;24:583–655.PubMedGoogle Scholar
  3. 3.
    Hille B: Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497–515.PubMedCrossRefGoogle Scholar
  4. 4.
    Rhodes DG, Sarmiento JG, Herbette LG: Kinetics of binding of membrane-active drugs to receptor sites. Mol Pharm 1985;27:612–623.Google Scholar
  5. 5.
    McClosky M, Poo MM: Rates of membrane associated reaction: reduction of dimensionality revisited. J Cell Biol 1986;102:88–96.CrossRefGoogle Scholar
  6. 6.
    Brown AM, Kunze DL, Yatani A: The agonist effect of dihydropyridines on Ca channels. Nature 1984;311:570–572.PubMedCrossRefGoogle Scholar
  7. 7.
    Kokubun S, Reuter H: Dihydropyridine derivatives prolong the open state of Ca channels in cultured cardiac cells. Proc Nat Acad Sci USA 1984;81:4824–4827.PubMedCrossRefGoogle Scholar
  8. 8.
    Herbette LG, Trumbore M, Chester DW, Katz AM: Possible molecular basis for the pharmacodynamics of three membrane active drugs: propranolol, nimodipine, amiodarone. J Mol Cell Cardiol 1988;20:373–378.PubMedCrossRefGoogle Scholar
  9. 9.
    Herbette LG, Katz AM, Sturtevant JM: Comparisons of the interaction of propranolol and timolol with model and biological membrane systems. Mol Pharm. 1983;24:259–269.Google Scholar
  10. 10.
    Chester DW, Herbette LG, Mason RP, Joslyn AF, Triggle DJ, Koppel DE: Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers. Biophys J 1987;52:1021–1030.PubMedCrossRefGoogle Scholar
  11. 11.
    Frenzel J, Arnold K, Nuhn P: Calorimetric, 13C NMR, and 31P NMR studies on the interaction of some phenothiazine derivatives with dipalmitoyl phosphatidylcholine model membranes. Biochim Biophys Acta 1978;507:185–197.PubMedCrossRefGoogle Scholar
  12. 12.
    Mason RP, Campbell SF, Wang S-D, Herbette, LG: Comparison of location and binding for the positively charged 1,4-dihydro-pyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac mambranes. Mol Pharm 1989;36:634–640.Google Scholar
  13. 13.
    Trumbore MD, Chester DW, Moring J, Rhodes D, Herbette LG: Structure and location of amiodarone in a membrane bilayer as determined by molecular mechanisms and quantitative X-ray diffraction. Biophys J 1988:54:535–543.PubMedCrossRefGoogle Scholar
  14. 14.
    Chatelain P, Laruel R, Gillard M: Effect of amiodarone on membrane fluidity and Na+/K+ ATPase activity in rat-brain synaptic membranes. Biochem Biophys Res Comm 1985;129:148–154.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • Arnold M. Katz

There are no affiliations available

Personalised recommendations